Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2022

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.

F. Onida
  • Fonction : Auteur
G. Sbianchi
  • Fonction : Auteur
A. Radujkovic
  • Fonction : Auteur
K. Sockel
  • Fonction : Auteur
N. Kröger
  • Fonction : Auteur
J. Sierra
  • Fonction : Auteur
J. Cornelissen
  • Fonction : Auteur
X. Poiré
  • Fonction : Auteur
L. Raida
  • Fonction : Auteur
J. Finke
  • Fonction : Auteur
J. Passweg
  • Fonction : Auteur
U. Salmenniemi
  • Fonction : Auteur
H. C. Schouten
  • Fonction : Auteur
Y. Beguin
  • Fonction : Auteur
S. Martin
  • Fonction : Auteur
A. Ganser
  • Fonction : Auteur
S. Zver
  • Fonction : Auteur
R. Rohini
  • Fonction : Auteur
L. Koster
  • Fonction : Auteur
P. Hayden
  • Fonction : Auteur
S. Iacobelli
  • Fonction : Auteur

Résumé

Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)–CMML: WBC 10–20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.

Dates et versions

hal-04505812 , version 1 (15-03-2024)

Identifiants

Citer

F. Onida, G. Sbianchi, A. Radujkovic, K. Sockel, N. Kröger, et al.. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.. Bone Marrow Transplantation, 2022, Bone Marrow Transplant, 57, pp.896-902. ⟨10.1038/s41409-021-01555-9⟩. ⟨hal-04505812⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More